For laboratory research use only - not for human consumption

Compound hub · Retatrutide

How long has retatrutide been studied?

The first dated human work on retatrutide began on 18 December 2019. That is when enrollment opened for a first-stage safety trial in people with type 2 diabetes (Urva et al., The Lancet, 2022; NCT04143802). Retatrutide has since entered large late-stage (Phase 3) testing. ClinicalTrials.gov NCT05929066 lists the TRIUMPH-1 trial as starting on 10 July 2023.

Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.

Published 2026-08-19Updated 2026-08-19Written by Form Laboratories research team10 min read

You have felt a meal land. About twenty minutes after the first bite, something in you decides you have had enough. That feeling has chemistry behind it. Your gut sends messages to your brain every time you eat. A molecule built to work with those messages makes headlines, and the natural question is whether anyone has studied it, and for how long.

This page is part of the retatrutide hub. It answers that question with dates. Retatrutide's record lives in two places. Trial registries stamp when people enrolled. Journals stamp when results went public. Side by side, they give a clear timeline, from a December 2019 enrollment window to a Phase 3 programme maturing in 2026.

  • Guidethe retatrutide hubRetatrutide research hub: what the compound is, which receptor systems the literature maps it to, what the published trials measured, and how it compares with approved medicines.

Key facts

Key facts for How long has retatrutide been studied?
Common nameretatrutide
Research codeLY3437943
DeveloperEli Lilly
CAS2381089-83-2
First characterisation paperCoskun et al., Cell Metabolism, 2022
Earliest dated human enrollment18 December 2019 (NCT04143802)
Phase 2 obesity trial published26 June 2023 (New England Journal of Medicine)
Phase 3 obesity trial start10 July 2023 (TRIUMPH-1, NCT05929066)
TRIUMPH-1 study completion30 April 2026 (registry, actual)
First peer-reviewed Phase 3 paperBajaj et al., The Lancet, June 2026 (TRANSCEND-T2D-1)
Dated human research spanDecember 2019 – August 2026
Trial phase as of 2026Phase 3
Approval as of 2026Approved in no country
The Lancet 2022Cell Metabolism 2022ClinicalTrials.gov NCT04143802

How long has retatrutide been studied?

Retatrutide's earliest dated human enrollment is 18 December 2019. It was a Phase 1b multiple-ascending-dose trial. That is a first-stage safety trial in which each group of volunteers got a series of slowly larger doses (Urva et al., The Lancet, 2022; NCT04143802). The compound was first described in public in 2022 (Coskun et al., Cell Metabolism, 2022). The retatrutide research guide traces the record from there. So dated human research runs from December 2019 to 2026. As of 2026 retatrutide is in Phase 3 trials.

Two kinds of date matter here, and they answer different questions. A registry date shows when a trial enrolled people. A publication date shows when the world could read about it. Retatrutide's registry record reaches back to December 2019. Its first journal paper came out in 2022. So the compound was under study in people for nearly three years before its name appeared in print. Both dates are real. They measure different things.

  • GuideThe retatrutide research guideA plain-English guide to LY3437943: what it is, the three receptor systems, what each trial phase found, and where the evidence stops.
Cell Metabolism 2022ClinicalTrials.gov NCT05929066Eli Lilly press release, 21 May 2026

Evidence limits

What does the research record not show?

Retatrutide's research record has four gaps. First, no first-synthesis or first-lab date is published. The year 2022 marks the first paper describing the compound (Coskun et al., Cell Metabolism, 2022). It is not a discovery date. Second, no enrollment window is dated for the first single-dose study in people. The earliest dated human start is 18 December 2019, when Phase 1b multiple-ascending-dose enrollment opened (Urva et al., The Lancet, 2022). Third, no peer-reviewed outcomes paper exists for the Phase 3 obesity programme as of 2026. TRIUMPH-1 shows 'No Results Posted' on ClinicalTrials.gov (NCT05929066). Fourth, no regulator has approved retatrutide in any country as of 2026.

Two widely quoted figures need their labels kept on. The 80-week and 104-week TRIUMPH-1 weight-change numbers are a company topline that Eli Lilly released on 21 May 2026. That is a press release, not a peer-reviewed result. The often-cited 24.2% body-weight change is the 48-week result for the 12-mg group. It is a least-squares mean, which is an average adjusted by a model, from 338 adults (Jastreboff et al., NEJM, 2023). It is not the 24-week primary endpoint of that trial.

Comparisons also run ahead of the evidence. No published head-to-head trial of retatrutide against tirzepatide or semaglutide exists as of 2026. TRIUMPH-5 (NCT06662383) is listed as active and not recruiting. The one published Phase 3 paper is TRANSCEND-T2D-1 (Bajaj et al., The Lancet, 2026). It is a 40-week trial in type 2 diabetes with retatrutide on its own, not added to another medicine. It is not the obesity Phase 3 package. The day-43 body-weight result in the first paper on the compound (Coskun et al., Cell Metabolism, 2022) is a single-dose Phase 1 measure of what the body did after one dose. It is not an efficacy result.

Even the headcounts differ. The TRIUMPH-1 registry entry lists 2,335 participants enrolled. Eli Lilly's 21 May 2026 company topline reports 2,339 randomised. The two figures come from different counting points, so they are not interchangeable. The record does not explain the gap, and neither does this article.

The Lancet 2022Cell Metabolism 2022

When did retatrutide first enter human trials?

Retatrutide's first dated human trial opened enrollment on 18 December 2019. That Phase 1b multiple-ascending-dose trial enrolled 72 people with type 2 diabetes. Enrollment closed on 28 December 2020. The trial reported a half-life of about six days. The paper says this supports a once-weekly schedule (Urva et al., The Lancet, 2022). An earlier Phase 1 single-ascending-dose study appears in the first paper on the compound (Coskun et al., Cell Metabolism, 2022). That record does not date its enrollment window. So 18 December 2019 stays the earliest dated human enrollment on record.

Read the two Phase 1 studies as a pair. The undated one came first, and the dated one built on it. Early safety work often shows up later in a paper that describes the compound. That is how the single-ascending-dose data reached print in 2022 (Coskun et al., Cell Metabolism, 2022). The record does not let us turn that gap into a date. Human work on retatrutide was under way by 18 December 2019, and probably earlier, but the earlier part is undated. The Phase 1b paper also recorded a week-12 body-weight change of up to −8.96 kg in the 3/6/9/12-mg group, after the placebo group's change was subtracted (Urva et al., The Lancet, 2022). The 90% confidence interval is the range the true figure most likely falls in. It ran from −11.16 to −6.75. That is a signal seen over twelve weeks inside a safety trial. It is not a verdict on efficacy.

NEJM 2023The Lancet 2023

What did the Phase 2 trials measure?

Two Phase 2 trials of retatrutide reported in 2023. In the obesity trial, 338 adults were followed for 48 weeks. The 12-mg group averaged a 24.2% body-weight change, against 2.1% on placebo (Jastreboff et al., New England Journal of Medicine, 2023). The primary endpoint of that trial was the 24-week change. So 24.2% is a 48-week figure, not the primary result. The diabetes trial randomised 281 participants across 42 US centres. HbA1c is a three-month blood-sugar marker. It changed by 2.02 points to 24 weeks in the 12-mg escalation arm, against 0.01 on placebo (Rosenstock et al., The Lancet, 2023).

A percentage only means something when it stays tied to the trial that produced it. So the details matter: 48 weeks, 338 adults, the 12-mg arm, and a placebo group that barely moved. At 48 weeks that same 12-mg group reached a body-weight change of 5% or more in 100% of participants, 10% or more in 93%, and 15% or more in 83%. On placebo the figures were 27%, 9% and 2% (Jastreboff et al., NEJM, 2023). The diabetes trial tells its own story. Body weight at 36 weeks changed by −16.94% against −3.00% on placebo. The dulaglutide 1.5-mg comparator arm had an HbA1c change of −1.41 points (Rosenstock et al., The Lancet, 2023).

Numbers like these invite a league table. The fair version of that comparison puts the same molecule beside approved medicines, states its criteria and ranks nothing. It lives in how retatrutide, Mounjaro, and Ozempic differ.

ClinicalTrials.gov NCT05929066Eli Lilly press release, 21 May 2026

What stage is retatrutide at in 2026?

Retatrutide is in Phase 3 obesity trials as of 2026. They run under one master protocol, which is a single trial design covering several sub-studies. It is registered as TRIUMPH-1 (ClinicalTrials.gov NCT05929066). The registry entry records an actual study start of 10 July 2023, an enrollment of 2,335 participants, and an actual study completion of 30 April 2026. The results tab shows 'No Results Posted'. Eli Lilly shared 80-week topline figures in a company press release on 21 May 2026. That is a company topline, not a peer-reviewed trial result. The protocol pairs an 80-week main period with a 24-week extension. The registry records an actual primary completion of 6 April 2026.

The topline figures come from Eli Lilly's 21 May 2026 company press release, not a journal. The release reports an 80-week efficacy estimand. That is the exact quantity a trial sets out to estimate. The average baseline was 112.7 kg (BMI 40.0). Mean body-weight reductions were −28.3% in the 12-mg arm, −25.9% in the 9-mg arm and −19.0% in the 4-mg arm, against −2.2% on placebo. A company topline arrives before the methods paper does. So these numbers sit in a different class of evidence from everything in the citations list.

The registry cannot smooth out one wrinkle. ClinicalTrials.gov NCT05929066 lists 2,335 participants enrolled, while the 21 May 2026 Lilly company topline says 2,339 were randomised. Enrollment and randomisation are different counting points. Neither source explains the gap, and both figures stand.

The Lancet 2026

Has any Phase 3 result been published in a journal?

One Phase 3 trial of retatrutide has been published in a journal as of 2026. TRANSCEND-T2D-1 ran for 40 weeks in 537 adults with type 2 diabetes. Their blood sugar was not controlled by diet and exercise alone (Bajaj et al., The Lancet, 2026). The trial ran across 48 sites. People were randomised to one of three retatrutide arms or to placebo. It measured blood-sugar control, not obesity outcomes, so it sits outside the TRIUMPH obesity programme. The Phase 3 results for the obesity programme have not appeared in a journal.

TRANSCEND-T2D-1 randomised its 537 participants to the 4-mg, 9-mg and 12-mg arms or to placebo. The groups held 134, 133, 136 and 134 people. Of the 537, 490 finished on drug, which is 91% (Bajaj et al., The Lancet, 2026). The same paper records HbA1c changes of −1.69%, −1.86% and −1.94% across the three retatrutide arms, against −0.81% on placebo. Body-weight changes were −11.5%, −13.9% and −15.3%, against −2.6%. This is a solid, peer-reviewed Phase 3 result. It aims at blood sugar in type 2 diabetes, which is a different question from the one TRIUMPH-1 asks.

Is retatrutide approved anywhere?

Retatrutide holds no regulatory approval in any country as of 2026. The FDA, the TGA and every other regulator have not approved it. It remains an investigational compound. Research material is not a medicine, is not a substitute for one, and is not for human or animal use. Approval needs a finished Phase 3 evidence package that a regulator has assessed. The obesity Phase 3 registry entry shows no results posted as of 2026 (ClinicalTrials.gov NCT05929066).

What legally exists is laboratory reference material, sold for research use. Form Laboratories lists retatrutide reference material as freeze-dried laboratory stock, which is not a medicine. Reading laboratory paperwork is its own skill. It covers what a certificate records, what a third-party report can and cannot prove, and how a batch stays traceable. The quality and verification hub walks through it.

Comparison

Dated record as of 2026: registry and journal dates only. Undated events are marked as such. This table is not a forecast.

Comparison: How long has retatrutide been studied?
DateEventSource
18 December 2019Phase 1b multiple-ascending-dose enrollment opens; earliest dated human enrollmentUrva et al., The Lancet, 2022; NCT04143802
28 December 2020Phase 1b enrollment closesUrva et al., The Lancet, 2022
September 2022First public characterization of LY3437943, with Phase 1 single-ascending-dose data (epub August 2022)Coskun et al., Cell Metabolism, 2022
November 2022Phase 1b multiple-ascending-dose trial publishedUrva et al., The Lancet, 2022
26 June 2023Phase 2 obesity trial published (epub); first paper using the name retatrutideJastreboff et al., NEJM, 2023
10 July 2023TRIUMPH-1 actual study startClinicalTrials.gov NCT05929066
August 2023Phase 2 type 2 diabetes trial publishedRosenstock et al., The Lancet, 2023
6 April 2026TRIUMPH-1 actual primary completionClinicalTrials.gov NCT05929066
30 April 2026TRIUMPH-1 actual study completionClinicalTrials.gov NCT05929066
21 May 2026Eli Lilly company topline on TRIUMPH-1 (press release, not a paper)Eli Lilly & Co. press release
June 2026TRANSCEND-T2D-1 published; first peer-reviewed Phase 3 paperBajaj et al., The Lancet, 2026

FAQ

How long has retatrutide been studied?

Dated human research on retatrutide runs from 18 December 2019, when Phase 1b enrollment opened (Urva et al., The Lancet, 2022), to 2026. The first public description came in 2022 (Coskun et al., Cell Metabolism, 2022). No first-synthesis date is published.

When did retatrutide Phase 3 trials start?

Retatrutide's Phase 3 obesity programme opened on 10 July 2023. That is the actual study start date logged for TRIUMPH-1 (ClinicalTrials.gov NCT05929066). The registry shows the trial as finished on 30 April 2026.

What is TRIUMPH-1?

TRIUMPH-1 is the Phase 3 obesity master protocol for retatrutide. It enrolled 2,335 participants, with an 80-week main period plus a 24-week extension (ClinicalTrials.gov NCT05929066). The registry shows no results posted as of 2026.

Is retatrutide approved?

No. As of 2026 no regulator anywhere has approved retatrutide. It remains an investigational compound in Phase 3 trials.

Have retatrutide Phase 3 results been published?

One retatrutide Phase 3 trial has been published. It is TRANSCEND-T2D-1, a 40-week trial in type 2 diabetes (Bajaj et al., The Lancet, 2026). The obesity Phase 3 results remain unpublished as of 2026.

Citations

5 sources
  1. Coskun T et al. Cell Metabolism. 2022;34(9):1234-1247.e9.
    doi:10.1016/j.cmet.2022.07.013

  2. Urva S et al. The Lancet. 2022;400:1869-1881.
    doi:10.1016/S0140-6736(22)02033-5

  3. Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
    doi:10.1056/NEJMoa2301972

  4. Rosenstock J et al. The Lancet. 2023;402:529-544.
    doi:10.1016/S0140-6736(23)01053-X

  5. Bajaj HS et al. The Lancet. 2026;407(10546):2402-2413.
    doi:10.1016/S0140-6736(26)00967-0

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Continue

Retatrutide reference material

Research use only, not for human or animal use.

Read the retatrutide research guide

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease